Dermatologicals
Refine search
Pharmaceutical
US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA trial evaluating upadacitinib in severe alopecia areata (AA). 8 August 2025
Biotechnology
US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business update.
Revenue grew by 4% year-over-year to $3.68 billion, outpacing forecasts of $3.30 billion. 1 August 2025
Biotechnology
The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM) is projected to grow from $1.84 billion in 2024 to $7.83 billion in 2034, registering a compound annual growth rate (CAGR) of 15.6%. 31 July 2025
Pharmaceutical
UCB, Belgium’s largest drugmaker, today released financial results for first half 2025, showing total revenue in increased to 3.49 billion euros ($4.02 billion), a rise of 25% (+26% constant exchange rate: CER). UCB’s shares were up 5.5% at 95.50 euros in early trading. 31 July 2025
Biotechnology
US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company (NewCo) focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. 29 July 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. 24 July 2025
Biotechnology
Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ Immunobody DNA active immunotherapies in combination with checkpoint inhibitors in advanced unresectable melanoma. 23 July 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis, submitted by US pharma major Bristol Myers Squibb. 21 July 2025
Biotechnology
Indian pharma major Sun Pharma reported positive top-line results from two late-stage studies of its psoriasis drug Ilumya (tildrakizumab), showing it helped reduce joint inflammation in people with active psoriatic arthritis. 21 July 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated April 10, 2025, Sun and Incyte Corporation have entered into a settlement and license agreement regarding litigation related to Leqselvi (deuruxolitinib). 15 July 2025
Biotechnology
German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license and transfer agreement to commercialize and advance the development of Spevigo (spesolimab). 14 July 2025
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites. 9 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Biotechnology
Italian drugmaker Philogen has announced its decision to voluntarily withdraw the application for marketing authorization to the European Medicines Agency (EMA) for Nidlegy(daromun), a biological investigational medicinal product which is intended to be used for the neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma. 27 June 2025
Biotechnology
US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported the successful outcome of a study related to atopic dermatitis. 24 June 2025
Biotechnology
New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its subsidiary Libertas Bio has licensed gusacitinib to Sanofi, expanding the partnership between the companies. 24 June 2025
Biotechnology
Further expanding the indications for French pharma major Sanofi’s mega-blockbuster Dupixent (dupilumab), the US Food and Drug Administration (FDA) has approved the drug for the treatment of adult patients with bullous pemphigoid (BP). 20 June 2025
Biotechnology
Spanish skincare specialist Almirall has promised a key contribution at the International Congress of Dermatology (ICD), currently taking place in Rome, Italy. 19 June 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has today recommended Spevigo (spesolimab) for the treatment of generalized pustular psoriasis (GPP) flares in adults in England and Wales. 18 June 2025
Biotechnology
Californian biotech Jasper Therapeutics presented data from the 180mg cohort of the company’s SPOTLIGHT Phase Ib/IIa study of subcutaneous briquilimab in adult participants with chronic inducible urticaria (CIndU) at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. 16 June 2025
Biotechnology
USA-based clinical-stage dermatology start-up Veradermics has announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. 5 February 2026
Biosimilars
Russian drugmaker Binnopharm Group together with China’s Mabwell announced plans to localize the production of a monoclonal antibody (MAb)-based drug for the treatment of asthma and atopic dermatitis in Russia. 4 February 2026
Biotechnology
Belgium’s largest drugmaker UCB today announced three-year data from the BE HEARD trials^ for Bimzelx (bimekizumab) in moderate to severe HS. 4 February 2026
Biotechnology
US clinical-stage biotech Sagimet Biosciences’ shares rose 10% to $6.23 after it announced that China-based partner Ascletis Pharma reported positive top-line results in the open-label Phase III trial evaluating the long-term safety of ASC-40 (denifanstat) tablets in patients with moderate to severe acne. 3 February 2026
Biotechnology
The US Food and Drug Administration (FDA) last week lifted the clinical hold on Intellia Therapeutics’ investigational new drug (IND) for its nexiguran ziclumeran (nex-z) for amyloidosis. The US Centers for Medicare and Medicaid Services (CMS) has released the names of 15 more drugs for a third cycle of Medicare price negotiations. On the deal-making front, Moderna signed a commercialization collaboration with Italy’s Recordati on mRNA-3927, and Japan’s Kyowa Kirin revealed that its partner Amgen has terminated the collaboration on dermatology candidate rocatinlimab. 1 February 2026
Biotechnology
Japanese drugmaker Kyowa Kirin late Friday announced the termination of the current rocatinlimab development and commercialization collaboration with US biotech major Amgen. 31 January 2026
Biotechnology
US biotech major Regeneron has presented its financial results for the fourth quarter and full year 2025. 30 January 2026
Pharmaceutical
French pharma major Sanofi reported strong fourth-quarter and full-year results for 2025 on Thursday. 29 January 2026
Pharmaceutical
Spanish dermatology specialist Almirall has announced that China’s National Medical Products Administration (NMPA) has approved Seysara (sarecycline hydrochloride). 29 January 2026
Biotechnology
US drugmakers Moderna and Merck & Co last week released new data on the former’s intismeran autogene and Merck’s Keytruda in the treatment of melanoma. UK pharma major GSK announced an agreement to acquire RAPT Therapeutics, along with its ozureprubart for $2.2 billion. Johnson & Johnson was the first big pharma to announce fourth quarter 2025 financials and forecast further growth. Also of note, Janux Therapeutics entered a collaboration with Bristol Myers Squibb for its investigational oncology drug JANX007 that could earn the company $850 million. 25 January 2026
Biotechnology
Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), today delivered a robust body of evidence that supports amlitelimab’s potential in the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis (AD). 23 January 2026
Pharmaceutical
French drugmaker Ipsen announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. 22 January 2026
Pharmaceutical
US healthcare giant Johnson & Johnson has announced results for fourth-quarter and full-year 2025. 21 January 2026
Biotechnology
Californian biopharma Corvus Pharmaceuticals has announced positive results from cohort four of the randomized, blinded, placebo-controlled Phase I trial of soquelitinib in moderate to severe atopic dermatitis. 21 January 2026
Biotechnology
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new clinical data on its investigational mRNA-based individualized neoantigen therapy (INT). 20 January 2026
Pharmaceutical
US commercial-stage biopharma Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance (Nasdaq: HRZN), with $30 million funded at closing and up to $20 million available if certain milestones are met. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-interleukin (IL)-15 antibody, TEV-'408. 12 January 2026
Biotechnology
The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, Vida Ventures and Platanus. 8 January 2026
Biotechnology
Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. 7 January 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze